Advanced search
Publication Cover
Journal of Pain Research Volume 16, 2023 - Issue
Submit an article Journal homepage
492
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series

Anne Marie McKenzie-Brown1 Department of Anesthesiology, School of Medicine, Emory University, Atlanta, GA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2679-5764View further author information
ORCID Icon,
David W Boorman1 Department of Anesthesiology, School of Medicine, Emory University, Atlanta, GA, USAView further author information
,
Kristen R Ibanez2 School of Medicine, University of Central Florida, Orlando, FL, USAView further author information
,
Ezihe Agwu3 Department of Anesthesiology, Vassar Brothers Medical Center, Poughkeepsie, NY, USAORCID Iconhttps://orcid.org/0000-0001-8064-9667View further author information
ORCID Icon &
Vinita Singh1 Department of Anesthesiology, School of Medicine, Emory University, Atlanta, GA, USAORCID Iconhttps://orcid.org/0000-0002-8103-1401View further author information
ORCID Icon
Pages 1993-1998 | Received 19 Oct 2022, Accepted 02 Jun 2023, Published online: 14 Jun 2023

References

  • Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi:10.1007/s10067-014-2517-2
  • Hatfield E, Phillips K, Swidan S, Ashman L. Use of low-dose naltrexone in the management of chronic pain conditions: a systematic review. J Am Dent Assoc. 2020;151(12):891–902.e1. doi:10.1016/j.adaj.2020.08.019
  • Srinivasan A, Dutta P, Bansal D, Chakrabarti A, Bhansali AK, Hota D. Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: a randomized, double-blind, active-control, crossover clinical trial. J Diabetes. 2021;13(10):770–778. doi:10.1111/1753-0407.13202
  • Martin SJ, McAnally HB, Okediji P, Rogosnitzky M. Low-dose naltrexone, an opioid-receptor antagonist, is a broad-spectrum analgesic: a retrospective cohort study. Pain Manag. 2022;12:699–709. doi:10.2217/pmt-2021-0122
  • Kim PS, Fishman MA. Low-dose naltrexone for chronic pain: update and systemic review. Curr Pain Headache Rep. 2020;24(10):64. doi:10.1007/s11916-020-00898-0
  • Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses. 2009;72(3):333–337. doi:10.1016/j.mehy.2008.06.048
  • Nicotra L, Loram LC, Watkins LR, Hutchinson MR. Toll-like receptors in chronic pain. Exp Neurol. 2012;234(2):316–329. doi:10.1016/j.expneurol.2011.09.038
  • Bruno K, Woller SA, Miller YI, et al. Targeting toll-like receptor-4 (TLR4)-an emerging therapeutic target for persistent pain states. Pain. 2018;159(10):1908–1915. doi:10.1097/j.pain.0000000000001306
  • Metz MJ, Daimon CM, Hentges ST. Reported Benefits of Low-Dose Naltrexone Appear to Be Independent of the Endogenous Opioid System Involving Proopiomelanocortin Neurons and β-Endorphin. eNeuro. 2021;8(3):ENEURO.0087–21.2021. doi:10.1523/ENEURO.0087-21.2021
  • Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538. doi:10.1002/art.37734

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.